問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Medical Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 710Tainan CityTainan Yongkang

Recruiting Trial

144Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

420Cases

2010-05-01 - 2011-04-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-12-01 - 2012-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-03-01 - 2006-03-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2024-12-20 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-07-22 - 2026-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Apalutamide (JNJ-56021927)

Participate Sites
7Sites

Recruiting7Sites

2019-11-01 - 2024-05-13

Phase II

Completed
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Erdafitinib

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting5Sites

Terminated6Sites

2018-10-30 - 2022-12-31

Phase III

Completed
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2005-10-01 - 2006-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2005-10-01 - 2006-10-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2025-01-03 - 2029-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 6 42
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB